The news you didn’t notice when reading about the $475,000 treamtent
David Augus and and Dana Goldman weigh in on Novartis’ decision to price their new chimeric antigen receptor T-cell (CAR-T) therapy known as Kymriah (tisagenlecleucel). The treatment represents ground-breaking technology, but is priced at $475,000 per treatment. But the authors note that there is something else novel about this technology: There was another announcement from…